The Data Gap That Sparked a National Mission
For decades, genomic research has been overwhelmingly Eurocentric. Roughly 86% of genome-wide association studies have focused on individuals of European descent, leaving Asian populations severely underrepresented in the reference datasets that underpin modern medicine. This gap isn’t merely academic—it translates into misdiagnoses, ineffective prescriptions, and missed opportunities for early intervention among billions of people.
Singapore decided to change that narrative. Through its National Precision Medicine (NPM) programme, coordinated by Precision Health Research, Singapore (PRECISE), the city-state has assembled a genomic resource of extraordinary scale and diversity.
What Makes PRECISE-SG100K Different
The PRECISE-SG100K study sequenced 100,000 Singaporean residents, capturing the country’s Chinese, Malay, and Indian ethnic composition. But the real breakthrough lies in what accompanies each genome: detailed lifestyle information including medical history, medication use, behavioural risk factors, mental health indicators, and socio-economic status. Singapore-specific food frequency data enables granular analysis of dietary patterns and nutrient intake.
This multi-layered approach allows researchers to ask questions that genomic data alone cannot answer. How do genetic predispositions interact with hawker-centre diets? Why do certain ethnic groups respond differently to the same diabetes medication? The NPM programme was built precisely to test whether integrating genomics with lifestyle and clinical data could improve outcomes and reduce costs.
From Research Cohort to Clinical Reality
Phase II of the NPM programme, which concluded with the PRECISE-SG100K cohort, linked genomic data with electronic health records in anonymised form for research use. This linkage proved transformative. It enabled the identification of population-specific risk variants—genetic markers that might be harmless in European populations but pathogenic in Asian contexts.
The programme’s impact has not gone unnoticed. In February 2026, Singapore’s NPM initiative received the Global Future Fit Seal Award at the World Governments Summit in Dubai, selected from over 1,500 nominations as an outstanding government initiative building capacity for future challenges.
A Real-World Signal: Pharmacogenomics in Psychiatry
One clinical implementation pilot illustrates the tangible difference this data makes. A patient diagnosed with major depressive disorder had experienced severe side effects from standard prescriptions—emotional numbing, excessive drowsiness, and reduced daily functioning. Through the Pre-emptive Pharmacogenomics (PPGx) pilot, the patient’s DNA was sequenced, and their psychiatrist received a report detailing how their genetic makeup affected drug metabolism and efficacy. The prescription was adjusted accordingly, and the patient regained emotional well-being and renewed interest in life.
This case, documented by CRIS Singapore in June 2026, demonstrates that precision health is not an abstract ambition—it is already reshaping individual treatment decisions in Singapore’s public hospitals.
The Road Ahead
Singapore’s approach offers a replicable framework for other nations wrestling with genomic diversity. The programme’s data governance protocols, consent frameworks, and clinical integration pathways are being studied internationally. As PRECISE expands its partnerships—including a bilateral memorandum with Genomics Australia signed in September 2026—the lessons from Singapore’s multi-ethnic cohort will inform precision health strategies across the Asia-Pacific.
